18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

BEAM News
Member News
Events

Latest news of BEAM Alliance

03 December 2019 - BEAM Alliance

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

The aim of the IMI Antimicrobial Resistance (AMR) Accelerator is to progress the development of new medicines to treat or…

18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

06 June 2019 - BEAM Alliance

Emergency on planet AMR: a vital pipeline to protect

The sooner we come up with practical solutions, the more SMEs (and currently developed products) we can save from vanishing.…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

page 1/3

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

25 February 2020 - ALLECRA THERAPEUTICS

Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections

“The superiority demonstrated in the primary endpoint, at test of cure, combined with a comparable safety profile to that of…

11 February 2020 - Da Volterra

Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients

“Results of this study showed that DAV132 could be safely administered to protect patients’ intestinal microbiota from antibiotic-induced disruption, thus…

05 February 2020 - MaaT Pharma

MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics

The proceeds will be used to complete the ongoing HERACLES Phase II clinical trial (NCT03359980),of MaaT’s lead compound, MaaT013, in…

27 January 2020 - DEINOVE

DEINOVE: Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections

"The start of this Phase II clinical trial is a significant step forward for DEINOVE and a great hope for…

07 January 2020 - Centauri Therapeutics Ltd

CARB-X backs Centauri to advance a new platform that combines antibiotic power with the ability to boost the immune system to fight infections caused by drug-resistant bacteria

The award will help Centauri continue the development of ABX01. The novel immunotherapy is in the lead optimization phase of…

06 January 2020 - Mutabilis SAS

Novo Holdings REPAIR Impact Fund Invests USD 12 million in Mutabilis and IBT Vaccines

Aleks Engel, Director of the REPAIR Impact Fund, commented: “We are thrilled to have Mutabilis and IBT Vaccines join the…

page 1/17

Events

13 December 2019

JPIAMR Hacking AMR 2019

Finding digital solutions to fight Antimicrobial Resistance is our theme for this special international JPIAMR hackathon. The hackathon aim is…

05 December 2019

Life Sciences Series #1

The Ark Life Science Series #1 provides an excellent opportunity to exchange with representatives from all relevant sectors (pharmaceutical companies,…

26 November 2019

REVIVE Webinar: Innovation in point-of-care diagnostics for sepsis and bloodstream infections

In this webinar our moderator Caroline Purslow (Nesta Challenges) will welcome three speakers. Till Bachmann (University of Edinburgh) will give…

13 November 2019

Matchmaking Symposium ‘Emerging Antimicrobials and Diagnostics in AMR 2019’

The event provides an excellent podium for emerging Antimicrobials and Diagnostics as well as an exciting program including orchestrated matchmakings,…

07 November 2019

World Anti-Microbial Resistance Congress

The conference gathers global leaders in infectious diseases to meet, brainstorm and discuss the challenges and opportunities on seven topic…

07 November 2019

REVIVE webinar: Converting Gram-positive-only compounds into broad-spectrum antibiotics

This webinar by Paul Hergenrother (Department of Chemistry and the Institute for Genomic Biology University of Illinois, US) will detail…

19 October 2019

4th International Course on Antibiotics and Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

03 October 2019

REVIVE webinar: Natural products antibiotics: from traditional screening to novel discovery approaches

In this webinar, Olga Genilloud will discuss the role of natural products in current antibiotic discovery.

02 October 2019

IDWeek 2019

IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America…

page 2/5